Meningococcal vaccines for administration via mucosa

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention concerns vaccines, particularly vaccines for meningococcal infections and diseases. Invention claims immunogenic composition for transport via mucosa, including capsular saccharides of at least two of the following serological groups: A, C and W135 and Y N. Meningitidis, as well as trialkylated chitosan.

EFFECT: enhanced production of immune response to meningococci in mucosa, possible balance shift of Th1/Th2 type responses.

16 cl, 24 dwg


The text descriptions are given in facsimile form.

1. Immunogenic composition for delivery via the mucous membrane, containing capsular saccharides, at least two of the following serological groups A, C and W135 and Y of N.meningitidis, and also containing trialkylamines chitosan.

2. Immunogenic composition comprising (a) capsular charigny antigen serological groups With N.meningitidis and (b) trialkylamines chitosan adjuvant.

3. The composition according to claim 2, containing (C) one or more additional antigens and/or (d) one or more additional adjuvants.

4. The composition according to claim 1, where these capsular saccharides conjugated to a protein(s)carrier(s) and/or are oligosaccharides.

5. The composition according to claim 3, where these capsular Oriental is s represent oligosaccharides, conjugated with protein(s)carrier(s).

6. The composition according to claim 1 or 2, containing capsular saccharides from 2, 3 or 4 serological groups a, C, W135 and Y of N. meningitidis.

7. The composition according to claim 6, containing sugars serological groups a+C, A+W135, A+Y, C+W135, C+Y, W135+Y, A+C+W135, A+C+Y, C+W135+Y or A+C+W135+y

8. The composition according to claim 1 or 2, prepared and/or packaged for intranasal.

9. The composition of claim 8, prepared in the form of an intranasal spray or nose drops.

10. The composition according to claim 1, containing additionally methoxycarbonyl mutant thermo-labile toxin of E. coli.

11. The composition according to claim 1 or 2, where the specified trialkylamines chitosan is trimethylchitosan.

12. The composition of claim 10, where the specified methoxycarbonyl mutant thermo-labile toxin of E. coli has a substitution of serine to lysine at residue 63.

13. The way of generating an immune response in a patient, introducing a patient a composition according to any one of claim 1 or 2.

14. The use of capsular saccharides, at least two of the following serological groups a, C, W135 and Y of N. meningitidis, where these capsular saccharides conjugated to a protein(s)carrier(s) and/or are oligosaccharides, and trialkylamines chitosan for the production of a drug for delivery to the animal through the mucous to develop his immune response.

15. PR is the application of (1) the capsular saccharide, at least one of the serological groups a, C, W135 and Y of N.meningitidis, where specified capsular saccharide anywhereman with protein(s)carrier(s) and/or it is an oligosaccharide, and (2) trialkylamines chitosan for the production of a drug for delivery to the animal through the mucous to develop his immune response.

16. Use 14 or 15, where the specified drug is intended for intranasal delivery.


Same patents:

FIELD: medicine, pharmaceutics.

SUBSTANCE: pharmaceutical composition includes fluoroquinolone antibiotic ofloksacin, tissue reparation stimulator methyluracil and local anesthetic lidocain hydrochloride as active components. Composition base part is polyethyleneoxides with mol weight of 400 and 1500, soluble in water. Also composition includes nipagin and nipasol conservation agents at the ratio of 4:1 and propyleneglycol as plasticiser. Composition is produced as soft sterile formulation. Composition shows aseptic properties in the absence of repeated contamination. Composition has antibacterial, anaesthetic, regeneration and wound healing effect.

EFFECT: obtaining composition with antibacterial, anaesthetic, regeneration and wound healing effect.

2 cl, 3 ex

FIELD: chemistry.

SUBSTANCE: invention concerns new depsipeptide compounds, as well as pharmaceutical compositions of these compounds and application of the compounds as antibacterial compounds.

EFFECT: methods of obtaining the new depsipeptide compounds and intermediary products applied in obtaining these compounds.

31 cl, 3 tbl, 25 ex

FIELD: chemistry.

SUBSTANCE: invention concerns crystalline azithromycin L-malate monohydrate of formula (I) with high stability, solubility and non-hygroscopicity. Also invention concerns pharmaceutical composition for microbe infection treatment, based on compound of the formula (I), and method of obtaining compound of the formula (I), involving: a) interaction of azithromycin with malic acid in aqueous organic solvent, or b) recrystallisation of water-free azithromycin L-malate from aqueous organic solvent.

EFFECT: obtaining crystalline azithromycin L-malate monohydrate of formula (I) with high stability, solubility and non-hygroscopicity.

15 cl, 7 tbl, 7 dwg, 18 ex

FIELD: chemistry.

SUBSTANCE: compounds of the invention have chemokine antagonistic properties and can be applied in treatment of immunoinflammatory diseases, such as atherosclerosis, allergy diseases. In general formula (I) R1 is hydrogen atom, (C1-C4)-alkyl, (C1-C4)-alkoxyl, cyclopropylmethoxy group, (C1-C4)-alkylthio group; R2 is halogen atom, (C1-C8)-alkyl, perfluoro-(C1-C4)-alkyl, (C3-C10)-cycloalkyl, phenyl, (C1-C8)-alkoxyl, values of the other radicals are indicated in the claim of the invention.

EFFECT: improved properties.

14 cl, 7 tbl, 20 dwg, 17 ex

FIELD: chemistry.

SUBSTANCE: invention concerns new compounds of the formula (I) and their pharmaceutically acceptable salts. Claimed compounds have antibacterial effect. In formula (I) , X is ; R1 is i) hydrogen, ii) (CH2)nNR5R6, iv) NRCO2R, v) (C1-6alkyl)CN, CN, (CH2)pOH; Y is NR*, O or S(O)p; is phenyl or 5-6-member heteroaryl with N or S as heteroatoms; R3 is NR(C=X2)R12, NR*R12, or -(O)n-5-6-member heteroaryl with 1-3 heteroatoms selected out of N, O, which can be linked over either carbon atom or heteroatom; the indicated 5-6-member heteroaryl can be optionally substituted by 1-3 groups of R7; R4, R4a, R4b and R4c are independently i) hydrogen, ii) halogen; other radicals are defined in the claim.

EFFECT: pharmaceutical composition containing effective volume of the claimed compound.

13 cl, 1 dwg, 194 ex

FIELD: medicine; veterinary science.

SUBSTANCE: strains Streptococcus pyogenes No 289 and Pseudomonas aeruginosa No 5292, 4762, 5271, 5211, and 5002 are grown up separately, inactivated and added with adjuvant. Thereafter produced monovaccines are mixed in equal ratio. Herewith used are daily culture of strain Streptococcus pyogenes No 289 containing 106x0.5 million micr.kl., strain Pseudomonas aeruginosa No 5292 with titre in "РТГА" 1:512, strains Pseudomonas aeruginosa No 4762 and No 5271 - with titre in "РП" 1:16, strains Pseudomonas aeruginosa No 5211 and No 5002 with titre in "РП" 1:16.

EFFECT: prevention of losses in reproduction of fur-bearing animals within farms with unfavourable streptococcal and pseudomonas infection conditions.

3 ex

FIELD: medicine.

SUBSTANCE: during acute period of purulent meningitis (BPM) additionally, Wobenzyme is prescribed in daily dose 1 tablet per 6 kg of body weight 3 times a day within 10 days simultaneously with antibacterial therapy. Treatment of meningococcal and pneumococcal meningitis is ensured with prescribed benzylpenicillin in daily dosage 300 thousand units/kg. Haemophilic meningitis is treated by prescribed Ceftriaxone in daily dose 100 mg/kg.

EFFECT: higher efficiency of BPM specific therapy due to Wobenzyme ability to improve antibiotic penetration through blood-brain barrier and transport to inflammatory tissue and autointoxication reduction.

3 cl, 2 tbl, 4 ex

FIELD: chemistry.

SUBSTANCE: invention concerns peptide compounds representing an amino acid sequence X1KEFX2RIVX3RIKX4FLRX5LVX6, where X1 is N-end segment which is IG; X2 is K or E; X3 is Q or E; X4 is D or R; X5 is N or E; X6 is C-end segment, which is a sequence selected out of PRTE or RPLR; where N-end segment is acetylated and/or C-end segment is amidated; with affinity to toxins, particularly to bacterial toxins, such as lipopolysaccharide or lipoteichoic acid. These compounds can inhibit or neutralise toxins. Invention also concerns pharmaceutical compositions and application of the claimed compounds in prevention or treatment of diseases or states caused by fungi or bacterial infection.

EFFECT: obtaining compounds for prevention or treatment of diseases or states caused by fungi or bacterial infection.

12 cl, 4 tbl, 4 ex

FIELD: medicine; biotechnologies.

SUBSTANCE: vaccine drug includes deactivated Escherichia coli bacteria of strain No 389 (078) and auxiliary substances. Additionally the drug includes aminoethylethyleneimine and liposome-forming mix as auxiliary substance at the following component rate in fluid form, wt %: aminoethylethyleneimine - 0.5-3; liposome-forming mix - 7.3-15; suspension of deactivated Escherichia coli bacteria of serotype 078 - 82.0-91.5.

EFFECT: harmless for fowl, enhanced antigenic and immunogenic activity.

3 cl, 4 tbl, 6 ex

FIELD: medicine; veterinary.

SUBSTANCE: medicine includes metal iodine and potassium iodide, prolongator and water. 1,2-propylene glycol is used as prolongator, and additionally vitamin A (retinol acetate), vitamin E (alpha-tocopherol acetate), vitamin B1 (thiamine hydrochloride), vitamin B2 (riboflavin), vitamin B6 (pyridoxine hydrochloride), vitamin B12 (cyanocobalamin), iron carbonate, magnium phosphate, manganese sulfate, copper sulfate, zinc sulfate, cobalt chloride, sodium chloride, amber acid, glucose, rectified ethyl alcohol (96%) are applied. Medicine components are taken at the following rate, g/100 ml of distilled water: metal iodine, chemically pure 0.112-0.187; potassium iodide, R 0.337-0.562; vitamin E (alpha-tocopherol acetate) 0.060-0.100; vitamin A (retinol acetate) 3.750-6.250 thousand mass units; vitamin B1 (thiamine hydrochloride) 0.052-0.087; vitamin B2 (riboflavin) 0.037-0.062; vitamin B6 (pyridoxine hydrochloride) 0.034-0.056; vitamin B12 (cyanocobalamin) 0.026-0.044; iron carbonate, R 0.337-0.562; magnium phosphate, R 0.337-0.562; manganese sulfate, R 0.172-0.287; copper sulfate, R 0.090-0.150; zinc sulfate, R 0.315-0.525; cobalt chloride, R 0.071-0.119; sodium chloride, R 0.589-0.981; amber acid, primary standard 0.225-0.375; glucose, AR 0.172-0.287; rectified ethyl alcohol (96%) 0.300-0.500 ml; 1,2- propylene glycol 0.900-1.500 ml. Method involves medicine administration with fodder in dosage of 1.00-1.50 mg per 1 kg of fish weight once per day for 5-7 days.

EFFECT: correction of needs for bioactive substances, prevention of avitaminosis, achievement of high antioxidant organism protection level, prevention of accumulation of non-saturated fatty acid peroxides harmful to fish.

2 cl, 3 tbl, 3 ex

FIELD: chemistry.

SUBSTANCE: invention pertains to modified polysaccharide in particular to modified polysaccharide Neisseria meningitidis of serogroup A, which preserves immunogenicity, but has improved stability. The modified polysaccharide is obtained from reaction of capsular polysaccharide, or its fragment - oligosaccharide, with CDI type bifunctional reagent, accompanied by reaction with an amino-compound, such as dimethylamine. Description is also given of modified polysaccharide conjugates and vaccines, which are obtained from such conjugates.

EFFECT: obtaining modified saccharide.

70 cl, 17 dwg

FIELD: medicine; veterinary science.

SUBSTANCE: method of higher meat production of broilers provides single injection for day birds of liposomal forms of preparation containing chimeric protein with water insoluble enzyme-inactive chloramphenicol acetyltransferase without 10 S-terminal aminoacids, aminoacid spacer (Sp)n, where n=1, 2, 4, 8 and somatostatin-14 with aminoacid sequence AGCFWKTFTSC, with median size of liposomes 250±50 nm. And preparation is introduced in combination with Marek's disease factor vaccine.

EFFECT: invention allows for higher effective meat production of broilers using single injection of preparation during the whole fattening period.

2 cl, 1 tbl

FIELD: chemistry.

SUBSTANCE: invention concerns aldehyde derivatives and conjugates of di-, oligo- or polysaccharide, of the general formula (I), methods of obtaining them, and pharmaceutical composition based on them and capable of staying in blood flow for prolonged time. , where R is -CH(CHO)CH2OH, -CH2CHO, -CH(CH2NHR1)CH2OH, -CH(CH2NHNHR1)CH2OH, -CH(CH=NNHR1)CH2OH, -CH2CH2NHR1, -CH2CH=N-NHR1, -CH2CH2NHNHR1; R1 is polypeptide or albumen; GlyO is a sialic acid bond; R3 is H; R4 is OH; n is 2 or more.

EFFECT: obtaining pharmaceutical composition based on aldehyde derivatives of sialic acid capable of staying in blood flow for prolonged time.

20 cl, 7 tbl, 22 dwg, 10 ex

FIELD: medicine; pharmacology.

SUBSTANCE: invention group refers to compositions containing hapten-carrier conjugate within arranged and repeating matrix, and method of related composition production. Offered hapten-carrier conjugate used for induction of agent-specified immune reaction in case of addiction or abuse, contains cortex particle including at least one first apposition site, where specified cortex particle is virus-like particle of RNA-phage, and at least one nicotine hapten with at least one second apposition site, where specified second apposition site is associated by at least one covalent non-peptide bond with specified first apposition site, thus forming arranged and repeating hapten-carrier conjugate. Offered conjugates and compositions under this invention can include virus-like particles connected to various haptens including hormones, toxins and agent, especially agents causing addiction, as nicotine and can be applied for induction of hapten immune reaction for therapeutic, preventive and diagnostic purposes.

EFFECT: vaccines can induce stable immune reactions for nicotine and fast reduce nicotine availability for brain absorbing.

31 cl, 6 dwg

FIELD: medicine, virology, immunology, molecular biology.

SUBSTANCE: invention involves a composition comprising a regulated and repeated matrix of antigens or antigen determinants and, in particular, matrix comprising RANKL protein, RANKL fragment or RANKL-VLP peptide. Invention relates to a composition comprising viral-like particle and at least one RANKL protein, RANKL fragment or RANKL peptide bound with its, and to a method for preparing conjugates and regulated and repeated matrices, respectively. Proposed compositions can be used for preparing vaccines used in treatment of bone diseases and as a pharmaceutical vaccine used for prophylaxis or treatment of bone diseases, and for effective induction of immune responses, in particular, humoral responses. The advantage of invention involves enhancing induction of immune responses to RANKL protein.

EFFECT: valuable biological and medicinal properties of matrices.

28 cl, 7 dwg, 20 ex

FIELD: medicine, polymers.

SUBSTANCE: invention relates to conjugates consisting of a water-soluble polymer of molecular mass from 200 to 20000 Da and representing polyethylene glycol or alkyl chain to which two molecules of synthetic peptides, not less, are bound by reactive functional group and wherein each peptide comprises amino acid sequence originating from region HR1 or HR2 of human immunodeficiency virus (HIV) gp41. Invention relates to methods for using these conjugates for delivery inhibition of to HIV target-cell by addition of indicated conjugates in the amount providing effective inhibition of cell infection with indicated virus. Also, invention relates to methods for preparing conjugates by functional adding of each molecule of synthetic peptide to polymer through reactive functional group.

EFFECT: valuable biological properties of conjugates.

27 cl, 2 dwg, 6 tbl, 6 ex

FIELD: chemical and pharmaceutical industry.

SUBSTANCE: invention relates to lyophilized pharmaceutical immunocytokine composition including immunocytokine and containing as cytokine component interleukin-2 (IL-2), sugar or aminosugar, amino acid and surfactant, wherein said composition contains: immunocytokines from 0.1 to 25 mg/ml; sugar or aminosugar 1-200 mg/ml; amino acid 1-200 mMol/l; and surfactant 0.001-1 mass %.

EFFECT: composition for parantheral administering with prolonged storage time even at increased temperatures.

13 cl, 8 ex, 4 tbl, 2 dwg

FIELD: medicine.

SUBSTANCE: method involves carrying out single-stage conjugate synthesis having stereospecific (affine) compound conjugated in covalent way to suspensoid carbon particles.

EFFECT: enabled direct analyte observation on solid phase surface as back spots; increased sensitivity of diagnosticum for performing immunochemical, gene-hybridizing and ligand-receptor studies and creating instrumentless rapid diagnosis test systems.

FIELD: chemical-pharmaceutical industry, proteins.

SUBSTANCE: invention concerns to cytokine-containing fused proteins showing the enhanced therapeutic index, and methods for enhancing the therapeutic index of these fused proteins. Fused proteins are able for binding with cytokine receptors of more one type expressed on cells and to bind with cells of more one type also. Except for, fused proteins possess a half-time value in blood stream of a patient as compared with that of corresponding natural cytokines.

EFFECT: improved and valuable properties of cytokines.

21 cl, 3 tbl, 11 ex

FIELD: medicine, radiation medicine.

SUBSTANCE: method involves subcutaneous administration of anti-influenza vaccine "Grippol" in the effective dose. Invention provides enhancing effectiveness of body to effect of ionizing radiation. Invention can be used for prophylaxis of radiation damage.

EFFECT: improved method of prophylaxis.

5 tbl, 2 ex

Neisseria antigens // 2347813

FIELD: chemistry; biochemistry.

SUBSTANCE: invented here are proteins of the meningococcus bacteria Neisseria meningitides (mainly strain B), with immunogenic properties. The proteins have defined amino acid sequences, presented in the description, and are coded with corresponding nucleotide sequences. Description is also given of an antibody, specific to the indicated meningococcus proteins. These proteins, coding their nucleotide sequences, as well as the specific antibody, can be used as an active ingredient in compositions for treating or preventing infection caused by Neisseria meningitides. The presented proteins can be used as antigens for making effective vaccines, immunogenic compositions.

EFFECT: obtaining proteins, used as ingredients for making effective vaccines, immunogenic compositions.

11 cl, 2 tbl, 104 ex